J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwara, A.
Right arrow Articles by Court, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwara, A.
Right arrow Articles by Court, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PHARMACOGENOMICS

Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation

Awewura Kwara, MBChB, MPH&TM, Margaret Lartey, MBChB, FWACP, Kwamena W. Sagoe, MSc, Fafa Xexemeku, MBChB, Ernest Kenu, MBChB, Joseph Oliver-Commey, MBChB, Vincent Boima, MBChB, Augustine Sagoe, BSc, Isaac Boamah, BSc, David J. Greenblatt, MD, FCP and Michael H. Court, BVSc, PhD

From The Miriam Hospital, Providence, Rhode Island (Dr Kwara); Warren Alpert Medical School of Brown University, Providence, Rhode Island (Dr Kwara); University of Ghana Medical School, Accra, Ghana (Dr Lartey, Mr Sagoe, Mr Boamah), Korle-Bu Teaching Hospital, Accra, Ghana (Dr Xexemeku, Dr Kenu, Dr Oliver-Commey, Dr Boima, Mr Sagoe); and Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (Dr Greenblatt and Dr Court).

The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT, and TT genotype frequencies were 0.27, 0.50, and 0.23, respectively. Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 µgxh/mL, P < .0001) or GG genotype (107 vs 23.0 µgxh/mL, P < .0001). Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P < 0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P < .0001). No differences in efavirenz exposure or CL/F existed between patients with CYP2B6 c.516GT and GG genotypes. Our results indicate that CYP2B6 c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co-treated with rifampin.

Key Words: Cytochrome P450 2B6 • genetic polymorphisms • efavirenz exposure • rifampin

Address for reprints: Awewura Kwara, MD, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906; e-mail: akwara{at}lifespan.org.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
G. Ramachandran, A. K. Hemanth Kumar, S. Rajasekaran, P. Kumar, K. Ramesh, S. Anitha, G. Narendran, P. Menon, C. Gomathi, and S. Swaminathan
CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 863 - 868.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology